Inve US ▾

Abbott (ABT) earnings

ABBOTT LABORATORIES· Health Care

Results to
Mar 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Abbott earnings: last reported Thu, 16 Jul 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue11,164 $ million+7.8% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin12.1 %−4.3 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit1,077 $ million−18.7% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Mar 2026

Guidance

What management said, and what became of it

16 of 22 judged targets kept · 34 open · verdicts reflect calls analysed to Jun 2026.

ABBOTT LABORATORIES management guidance track record: 56 targets tracked across analysed earnings calls (16 achieved, 6 missed, 34 open).

TargetOriginal wordingSaidLatest callVerdict
Adjusted earnings per share$1.25 to $1.31Mar 2026Jun 2026:Today, we issued second quarter results that included sales growth of 4.8%, which represents an acceleration compared to the previous 2 quarters and adjusted earnings per share of $1.31, which exceeded the midpoint of our guidance range and the consensus estimate.
Call transcript, Jun 2026 · no direct link		Achieved
CGM sales growthdouble-digit growthMar 2026Jun 2026:In Diabetes Care, continuous glucose monitoring sales exceeded $2 billion, reflecting growth of 9.5% in the quarter.
Call transcript, Jun 2026 · no direct link		Missed
Adjusted earnings per share$5.55 to $5.80Dec 2025Jun 2026:Considering our second quarter results, and updated outlook for the remainder of the year, we are reaffirming our full year guidance for comparable sales growth of 6.5% to 7.5% and raising our EPS guidance range to $5.45 to $5.60.
Call transcript, Jun 2026 · no direct link		Revised Up

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of ABBOTT LABORATORIES's 56 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 53 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$104.06 −0.79% · −$0.83

Last close Oct 19, 2026 · US · USD

Performance −19.0% 1Y

$80$90$100$110$120$130Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Aug 26Oct 26Sep 2025 (Q3 FY25) — 17 Oct 2025Dec 2025 (Q4 FY25) — 22 Jan 2026Mar 2026 (Q1 FY26) — 16 Apr 2026Jun 2026 (Q2 FY26) — 16 Jul 2026

1Y: $128.54 on 17 Oct 2025 → $104.06. High $130.59 (14 Nov 2025), low $82.56 (11 May 2026).

Previous close
$104.89
52-week range
$82.56 – $130.59
One year
−19.65%

Overview

Symbol
ABT
Exchange
US
Currency
USD

Your own record

Start an Inve Case for ABBOTT LABORATORIES

Free account. Everything above stays public.

Write why you follow ABBOTT LABORATORIES and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other companies in Health Care

Nearest to Abbott by market cap among the sector's top 20 companies at Q2 2026.

Health Care sector analysis

Other US companies filed under A

All 347 companies under A

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered